Simeon George bought $51.5M of CRISPR Therapeutics AG (CRSP)
Executed Jul 16 2025, disclosed Jul 17 2025, 1 day later.
Over the 21 trading sessions from the disclosed entry session (Jul 17 2025), the stock returned +5.3% (delay-adjusted); from the execution session (Jul 16 2025), +7.3%. Derived: entry at the session's open, exit at the close 20 sessions later.
Simeon George (Director) filed 2 Form 4 reports in the trailing twelve months (1 purchase, 1 sale), most often in CRISPR Therapeutics AG (CRSP). Across 1 priced purchase filing, the average 21-session return was -6.3% from execution and -8.9% from disclosure (delay-adjusted; derived). The largest single filing was $27.2M of ADRX (1,600,000 sh across 3 lots, as filed), executed Sep 28.
Healthcare · CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered R…
More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→14,514 sh × $49.63
Exec Oct 14
Filed Oct 16 · 5:45 PM ET